Mineralys Therapeutics stumbled into a pivotal week — pricing a dilutive equity offering at a steep discount to buy back royalty obligations on lorundrostat, right as the FDA clock ticks louder.
On June 3, the company priced a $150 million underwritten offering of 5.66 million shares at $26.50 each. That represented a roughly 8% discount to the prior close. The proceeds go toward repurchasing royalty obligations owed under the Tanabe license agreement — a move designed to strengthen the economics of lorundrostat ahead of a potential NDA decision. The strategic logic is defensible. The near-term price hit was not: the stock dropped 7.3% on the day to $28.85, adding to a 3.8% weekly decline.
The offering is the dominant story this week, but the short interest backdrop adds texture. Shorts have rebuilt meaningfully over the past month — SI % of free float has climbed from around 14.2% in late April to 15.0% now, after a brief spike above 16% in early May. That 4% week-on-week increase in short shares is the highest rate of re-accumulation in six weeks. Yet the borrow market itself tells a more relaxed story. Availability remains extremely loose at 552%, meaning roughly five-and-a-half shares are available for every one currently borrowed — there is no lending constraint on new short positions. Cost to borrow runs at just 0.5% annually, near the bottom of the range for any meaningful short. Shorts are rebuilding, but they're doing so cheaply and without urgency. The ORTEX short score at 62.5 — up steadily from 58.7 three weeks ago — confirms the directional drift.
Options positioning points the other way. Call demand has picked up relative to recent norms. The put/call ratio dropped to 0.56, roughly 1.5 standard deviations below its 20-day average of 0.64. That's the most bullish options read in the past year — touching the 52-week low of 0.53 set in late May. The move looks like pre-offering demand from participants who wanted leveraged upside exposure to a potential equity raise rather than outright stock. With dilution now confirmed and priced, that positioning will bear watching in coming sessions.
The Street remains broadly constructive. Analysts carry a mean price target near $48.50 — implying roughly 68% upside from current levels, a gap that has widened given the price drop. B of A Securities raised its target to $51 from $46 in March, maintaining Buy. TD Cowen initiated coverage in late April with a Buy rating. The bull case centres on lorundrostat's Phase 3 showing — a 10mmHg-plus placebo-adjusted blood pressure reduction in uncontrolled and resistant hypertension, with supportive 24-hour ambulatory data presented at the ESH 2026 conference this week. Bears point to commercial execution risk, hyperkalemia tolerability concerns, and dilution from repeated capital raises. The EPS momentum factor ranks in the 82nd percentile on a 30-day basis, suggesting estimate revisions have been tracking higher even as the share count grows.
Institutional holders are largely biotech-specialist funds who tend to view dilution as a feature rather than a bug when it cleans up the cap table. RA Capital Management added 369,000 shares in Q1. Wellington Management built a fresh position of 2.6 million shares. OrbiMed and Point72 each added over 1 million shares in the same period. On the insider side, CMO David Rodman sold approximately $665,000 worth of stock in May across several tranches — modest relative to the company's size and consistent with a pre-arranged plan. CEO Jon Congleton sold roughly $422,000 in April. Neither pattern is alarming in isolation, but the direction is worth noting alongside the equity raise.
Next earnings are not due until August 5. Between now and then, the focus narrows entirely to two things: any further FDA engagement on the NDA timeline for lorundrostat, and how the market digests the diluted share count against the improved royalty economics. The offering removes one overhang; it may introduce another.
See the live data behind this article on ORTEX.
Open MLYS on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
